Tirzepatide.
Tirzepatide (development code LY3298176) is a synthetic, 39-amino-acid modified peptide engineered as a "twincretin," a single molecule that activates two incretin hormone receptors at once.
Tirzepatide (development code LY3298176) is a synthetic, 39-amino-acid modified peptide engineered as a "twincretin," a single molecule that activates two incretin hormone receptors at once. Tirzepatide is fda-approved, and PepCue grades its published evidence S tier (92/100). Also known as Mounjaro · Zepbound. This is a research reference, not medical or dosing advice.
What it is
Tirzepatide (development code LY3298176) is a synthetic, 39-amino-acid modified peptide engineered as a "twincretin," a single molecule that activates two incretin hormone receptors at once. It carries a C20 fatty diacid side chain that binds serum albumin, extending its half-life to roughly five days and enabling once-weekly subcutaneous dosing. It is the active ingredient in Eli Lilly's FDA-approved products Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).
How it works
Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, the first approved agent to engage both incretin pathways. Through GLP-1 receptor activation it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways; GIP receptor activation contributes additional insulinotropic effects and is thought to influence energy metabolism and adipose tissue handling. Its peptide backbone is more closely modeled on native GIP, and it is biased toward GIP-receptor engagement relative to GLP-1, though the precise contribution of the GIP arm to its clinical effect in humans remains an area of active investigation. The net clinical result is improved glycemic control and substantial reductions in body weight and food intake.
Mechanism pathways
Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
Glucagon-like peptide-1 is an incretin hormone released from the gut after a meal. Its receptor is a class B G-protein-coupled receptor found on pancreatic beta cells, on stomach and gut tissue, and on neurons in the hypothalamus and brainstem, including the area postrema. When the receptor is activated, three things happen at once. Beta cells become more responsive to glucose, so insulin secretion rises mainly when blood glucose is already elevated rather than continuously, which is why this class carries a lower intrinsic hypoglycaemia risk than insulin itself. The stomach empties more slowly, flattening the rise in glucose after eating and prolonging the sense of fullness. Central appetite circuits shift toward satiety, reducing the drive to eat between meals. Glucagon secretion is also suppressed when glucose is high. Many compounds target this receptor because native GLP-1 is degraded within minutes by dipeptidyl peptidase-4. Almost every design problem in the class is a half-life problem, and the answers differ. Some analogs attach a fatty-acid chain so the molecule binds albumin and circulates far longer. Others alter the amino acids around the cleavage site so the enzyme cannot act. These structural choices set how often a compound is given and how steeply blood levels rise and fall, which in turn shapes how much nausea a person experiences during the early adjustment period. The class also splits by how many receptors a molecule touches. Pure GLP-1 agonists engage this pathway alone. Dual and triple agonists add GIP, glucagon, or amylin activity on top of it, and combination products pair a GLP-1 agonist with a separate molecule. In every case the GLP-1 arm remains the backbone of the metabolic effect. Of all the pathways described on this site, this one has the strongest and most mature clinical footing. Several GLP-1 receptor agonists are approved medicines for type 2 diabetes, for obesity, or both, and the mechanism has been characterised in humans rather than inferred from animal work. That does not make every molecule in the class equivalent. Some listed here are still investigational, and their receptor activity being well understood says nothing about whether their particular formulation, purity, or long-term profile has been established.
Activating the GIP receptor, a second incretin pathway, usually combined with GLP-1 activity.
Glucose-dependent insulinotropic polypeptide, usually shortened to GIP, is the other major incretin hormone. It is released from K cells in the upper small intestine after eating and acts on a class B G-protein-coupled receptor expressed on pancreatic beta cells, on adipocytes, on bone, and in several brain regions including the hypothalamus. Like GLP-1, it amplifies nutrient-stimulated insulin secretion, so insulin rises in proportion to how much glucose is present. Unlike GLP-1, it does not reliably suppress glucagon and does not slow gastric emptying to the same degree. GIP was studied for decades before it became a drug target, and for much of that time the field was pessimistic. In people with poorly controlled type 2 diabetes the insulin response to GIP appears blunted, which suggested the pathway was a dead end. Interest revived when it became clear that improving glucose control can restore some of that responsiveness, and that GIP receptor activity in fat tissue and in the brain may contribute to weight and appetite regulation through routes that do not overlap with GLP-1. Compounds in this group do not target GIP alone. They are engineered as dual or triple agonists that engage GIP alongside GLP-1, and in some cases glucagon as well, on a single peptide backbone. The design question is not simply whether to include GIP activity but in what ratio, since a molecule can be tuned to favour one receptor over another. Different agents in this space sit at different points on that balance, which is one reason their tolerability and their effect on body weight versus blood glucose are not identical. An unresolved and genuinely debated point is the direction of benefit. Both GIP receptor agonism and GIP receptor blockade have been pursued as approaches to weight management, and the biology that would explain how two opposite interventions could both help is not settled. What is established is that the combined GIP and GLP-1 molecules perform well in human trials and that at least one is an approved medicine. What remains uncertain is how much of that performance is attributable to the GIP arm specifically rather than to the GLP-1 backbone it is attached to.
The evidence
Human evidence for tirzepatide is unusually robust, anchored by the large randomized SURPASS (diabetes) and SURMOUNT (obesity) programs. In SURPASS-2 (Frias et al., NEJM 2021), tirzepatide produced greater HbA1c and body-weight reductions than injectable semaglutide in type 2 diabetes across all doses. In the placebo-controlled SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), adults with obesity or overweight lost roughly 15–21% of body weight on average depending on dose. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed reductions in apnea-hypopnea index in patients with obesity and moderate-to-severe obstructive sleep apnea, supporting the December 2024 FDA approval for that indication. A dedicated cardiovascular outcomes trial (SURPASS-CVOT) and the SUMMIT heart-failure-with-preserved-ejection-fraction program have reported results, but long-term hard-outcome data are newer and still being integrated; readers should treat cardiovascular benefit as supported but more recently established than the glycemic and weight findings.
The evidence, in brief
A dual GIP/GLP-1 receptor agonist with large randomized trials (SURMOUNT for weight, SURPASS for diabetes). FDA-approved as Mounjaro and Zepbound; program data show among the largest average weight reductions reported for a drug. Strongly evidenced, with the same GI-tolerability and continued-use caveats as other incretins.
- Jastreboff AM et al.: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)N Engl J Med, 2022 (PMID 35658024)
- Mounjaro / Zepbound (tirzepatide): FDA prescribing informationFDA / DailyMed
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #067
Approved or strong, consistent human evidence.
FDA-approved for a specific indication: the strongest lane.
Claim receipts
Popular claims about Tirzepatide, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Dual GIP/GLP-1 agonism shows very large weight-loss magnitude in trials relative to prior benchmarks.
Approved with trial safety data, but very-long-term real-world safety is still accumulating.
Head-to-head data favors it on weight loss on average, but individual response and tolerability vary.
Safety profile
The most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite, typically arising during dose escalation and often diminishing over time. The FDA label carries a boxed warning regarding thyroid C-cell tumors based on rodent studies (the human relevance is unknown), and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Documented risks include acute pancreatitis, gallbladder disease, acute kidney injury (often via dehydration from GI losses), hypersensitivity reactions, and hypoglycemia when combined with insulin or sulfonylureas. Important unknowns remain around long-term safety, effects of regained weight after discontinuation, use in pregnancy, and potential reduced effectiveness of oral medications (including oral contraceptives) due to delayed gastric emptying.
Compound notes
- Tirzepatide is a dual agonist: it activates both the GIP and GLP-1 receptors, two incretin pathways, in a single molecule.
- It is FDA-approved (brands Mounjaro for type-2 diabetes, Zepbound for weight management), supported by the SURPASS and SURMOUNT trial programs.
- It has a long half-life of about five days, the basis for once-weekly approved formulations.
Tirzepatide hits two incretin receptors (GIP + GLP-1); semaglutide hits one (GLP-1). Head-to-head data favored tirzepatide on average weight loss, but individual response and tolerability vary.
- Strong evidence for its approved uses; broader wellness/longevity claims are not approved or proven.
- Common effects are gastrointestinal; see the FDA label for warnings and contraindications.
Regulatory status
Tirzepatide is FDA-approved (not investigational): as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (November 2023) and moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024); it is also authorized in the EU, UK, and other jurisdictions. It is a prescription drug, and compounded or research-grade "tirzepatide" sold outside the regulated supply chain is not FDA-approved and carries quality and safety risks.
Approved by the FDA for at least one indication.
By the numbers
- 01First-in-class dual GIP/GLP-1 receptor agonist (a 39-amino-acid peptide), distinct from single-pathway GLP-1 agonists like semaglutide
- 02Marketed by Eli Lilly as Mounjaro (diabetes) and Zepbound (weight management and obstructive sleep apnea)
- 03Albumin-binding fatty-acid modification gives an ~5-day half-life, supporting once-weekly administration
- 04In the head-to-head SURPASS-2 trial it outperformed semaglutide on HbA1c and weight reduction in type 2 diabetes
- 05FDA approvals span 2022 (diabetes), 2023 (obesity), and 2024 (obstructive sleep apnea)
- 06Carries a boxed warning for thyroid C-cell tumors based on rodent data; human relevance is unknown
Tirzepatide: research formats
Choose the format you are researching to see route-specific notes.
Weekly SC injection. Zepbound titration is 4 steps over 16+ weeks.
Tirzepatide (Mounjaro for diabetes; Zepbound for weight) is a once-weekly subcutaneous injection administered via a single-use auto-injector pen. Dose escalation from the Zepbound prescribing information is below.
If tolerability is an issue, dose escalation can be delayed. Your prescriber determines when to advance.
Compounded tirzepatide is not the FDA-approved product and may differ in salt form, concentration accuracy, and sterility. The clinical trial evidence applies to the approved branded drugs.
Sources
Every factual claim above resolves to a real, published source.
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)New England Journal of Medicine, 2022, PMID 35658024
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)New England Journal of Medicine, 2021, PMID 34170647
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)New England Journal of Medicine, 2024, PMID 38912654
- MOUNJARO (tirzepatide) injection: FDA Prescribing InformationU.S. FDA / accessdata.fda.gov, 2022 (rev. 2025)
Cite this page
PepCue. “Tirzepatide: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/tirzepatide.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.